Endocrine oncology

Surgical Morbidity and Short-Term Oncologic Status after Prophylactic-Intent Thyroidectomy in a Cohort of Children with MEN2 from the Multicenter GTE ENDOCAN-RENATEN Study

ThyroidPublished Retrospective cohort study

Authors' conclusion

In this national contemporary cohort, prophylactic-intent thyroidectomy in pediatric MEN2 was associated with excellent short-term oncologic outcomes but also with a substantial rate of permanent hypoparathyroidism, particularly in very young children.

Study context

Population
Children <15 years with MEN2 germline RET mutations who underwent prophylactic-intent total thyroidectomy 2010–2020 without clinically apparent structural disease, French Groupe d'Étude des Tumeurs Endocrines61 MEN2A, 3 MEN2B
Participants
64 children
Outcome
Histopathology and oncologic status
Follow-up
Median 6 years (IQR = 2.4-8.5 years)
Methodological detailsnational, multicenter
  • National
  • Multicenter

Main finding

As reported in the abstract

C-cell hyperplasia
52%
Micro-MTC
34%
Lymph node metastases
3%
Persistent structural disease at last follow-up
0
Persistent moderate biochemical disease without structural evidence of medullary thyroid carcinoma (MTC)
1 patient

Observational data: associations, not effects.

Further findings

Preoperative calcitonin elevated

Elevated preoperative calcitonin, evaluable patients
44%

Age at surgery

Median age at surgery, years (IQR = 3.2-8.3 years)
4.6

Safety

Postoperative hypoparathyroidism

Hypoparathyroidism
31%
Permanent hypoparathyroidism, predominantly among children operated before age 5 years
16%

Original publication

Surgical Morbidity and Short-Term Oncologic Status after Prophylactic-Intent Thyroidectomy in a Cohort of Children with MEN2 from the Multicenter GTE ENDOCAN-RENATEN Study. Thyroid. Published 7 August 2026. doi:10.1177/10507256261477167

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.